Drugs / XM17
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02592031 | Feb → May 2009 | — | Merckle GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XM17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592031 ↗ |
| Modality | Protein / enzyme biologic | “XM17 is a recombinant human follicle-stimulating hormone (rhFSH)” PMID 26621118 ↗ Dec 2015 |
| Route | Subcutaneous | “single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f®” NCT02592031 ↗ |